GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.

GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna's lipid nanoparticles for transporting mRNA into the human body infringe several GSK patents covering similar innovations.

GlaxoSmithKline has filed lawsuits against Moderna in the U.S., claiming infringement on its mRNA technology patents with Moderna's COVID-19 vaccine, Spikevax. The legal action, part of a broader web of litigations also involving Pfizer and BioNTech,

A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.

GlaxoSmithKline (GSK) has filed a patent infringement lawsuit against Moderna in Delaware, accusing the company of using its patented mRNA technology in their Spikevax COVID-19 vaccine without permission.

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.